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Abstract
Breakthrough cancer pain is a common phenomenon, which is associated with a significant impact on 
quality of life. Management of BTcP is often suboptimal, and this reflects the heterogeneous nature of BTcP, 
and the often standardised (rather than individualized) management of BTcP. This article reviews national / 
international guidelines relating to BTcP, and highlights the ongoing controversies, such as the definition, 
diagnosis, and management of BTcP. However, many of these guidelines agree on the fundamental aspects 
of the management, and specifically about the important role of so-called “rapid onset opioids”.
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Introduction
Breakthrough cancer pain (BTcP) is a common phe-
nomenon, with a reported overall prevalence of 59.2% 
in patients with cancer pain [1]. It has a significant 
impact on quality of life, which relates not only to 
the pain itself [2], but also to the associated physical, 
psychological, and social problems [3]. Equally, it has 
a significant impact on health systems (due to the 
increased use of healthcare resources) [4].
Portenoy and Hagen first described the pheno-
menon of BTcP over 25 years ago [5]. Since then, 
many papers have been published on BTcP the topic, 
including many contemporary national/international 
guidelines on BTcP [6–14]. Nevertheless, there remain 
a number of controversies in terms of the definition, 
the diagnosis, and particularly the management of 
this condition. 
The aim of this paper is to highlight these contro-
versies, and to review the relevant recommendations 
in the national/international guidelines and relevant 
Delphi surveys of healthcare professionals [15, 16]. 
The Association for Palliative Medicine of Great Britain 
and Ireland (APM) recommendations were used as the 
so-called “reference” guideline for the discussion [6]. 
Definition of BTcP 
As discussed above, there is no consensus on the 
definition of BTcP [17]. The latter is important in terms 
of extrapolating the results of research studies, and 
even the recommendations of key opinion leaders.
The APM defined BTcP as “a transient exacerbation 
of pain that occurs either spontaneously, or in rela-
tion to a specific predictable or unpredictable trigger, 
despite relatively stable and adequately controlled 
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Webber et al have reported that the APM algorithm 
has a good positive predictive value (i.e. the propor-
tion of patients who screen positively using the algo-
rithm and are deemed to have BTcP by a pain specialist) 
[21]. It should be noted that, in this study, the ‘gold 
standard’ for diagnosing BTcP was a comprehensive 
assessment by a pain specialist, i.e. an experienced 
consultant in pain or palliative care.  
Some definitions [5], and diagnostic criteria [20] 
use “moderate” as the cut-off between controlled 
background pain and uncontrolled background pain. 
However, Webber et al have reported that using 
moderate (rather than “mild”) as the cut-off resul-
ted in a much lower positive predictive value (i.e. 
0.68 vs. 0.84) [21]. Webber et al have also reported 
that some patients with moderate background pain 
feel that their background pain is “adequately con-
trolled” [22].
Relationship to background pain
Breakthrough pain can only exist in the presence 
of background pain (see above) [6]. Nevertheless, pa-
tients with cancer may experience transient episodes 
of pain in the absence of background pain [23]. Re-
cently, the term “episodic” pain has been suggested 
to describe these (and other) transient episodes of 
background pain” [6]. This definition was derived 
from an earlier one proposed by Portenoy et al. [18]. 
Some of the national/international guidelines en-
dorse the APM definition [7, 9, 14], whereas others 
have developed their own definition for BTcP [8, 11, 
13]. Interestingly, a recent Delphi process on the dia-
gnosis and management of BTcP involving Spanish 
healthcare professionals reported the highest level of 
agreement for the APM definition of BTcP [16]. 
Diagnosis of BTcP
The APM developed a diagnostic algorithm for 
BTcP (Fig. 1) [6, 19]. The algorithm was derived from 
an earlier one proposed by Portenoy et al [20], and 
enables the clinician to differentiate between patients 
with BTcP, patients with uncontrolled pain, and pa-
tients with intermittent/‘transitory’ pain. 
Again, some of the national/international guideli-
nes endorse the APM algorithm [7–9, 12, 14], whereas 
others either use other published diagnostic criteria 
[11] or have developed their own diagnostic criteria 
[13]. Interestingly, another recent Delphi process on 
the definition, assessment, management, and monito-
ring of BTcP involving Spanish healthcare professionals 
reported universal agreement for the APM diagnostic 
algorithm for BTcP [15].
Does the patient have transient
exacerbations of pain?
Patient has breakthrough pain Patient has not have breakthrough pain
Does the patient have background pain?
Background pain = pain present
for 12 hour/day durin previous week
(or would be present if not taking analgesia)
Is the background pain adequately controlled?
Adequately controlled = pain rated as „none”
or „mild”, but not „moderate” or „severe”
for > 12 hour/day during previous week
Patient does have 
breakthrough pain,
but does have 
uncontrolled background pain
Yes No
No
No
Yes
Yes
Figure 1. Association for Palliative Medicine of Great Britain and Ireland (APM) diagnostic algorithm for break-
through cancer pain [6, 19]
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pain that do not meet the diagnostic criteria for BTcP 
[24]. However, the choice of the term episodic pain 
is somewhat perplexing, because episodic pain has 
been used as a surrogate for BTcP in the past [25, 26].
Relationship to background 
medication
In 1990, Portenoy and Hagen defined BTcP as 
“a transitory exacerbation of pain that occurs on 
a background of otherwise stable pain in a patient 
receiving chronic opioid therapy” [5]. However, it 
was realised that the stipulation about background 
opioid medication was too restrictive [23], and so the 
definition was later amended to exclude any reference 
to background opioid medication [18]. 
The Spanish BTcP guideline’s definition of BTcP 
includes the use of opioid to control background 
pain [8]. However, the two Spanish Delphi surveys 
agreed that the prescription of a regular opioid was 
not required to make the diagnosis of BTcP [15, 16].
Frequency of BTcP episodes
Some authors have suggested that BTcP should be 
defined by the number of episodes per day, and that 
patients with more than four episodes per day should 
be considered to have uncontrolled pain, or should 
be treated in a different manner (i.e. modification of 
background medication rather than use of rapid-onset 
opioids) [9, 16]. It appears that the number four rela-
tes to the recommended dose frequency of so-called 
“rapid-onset opioids” (see later), rather than to any 
scientific rationale or data from clinical trials.
Choice of rescue medication
The APM recommendations state that opioids are 
the rescue medication of choice for BTcP, and that “the 
decision to use a specific opioid preparation should 
be based on a combination of the pain characteristics 
(onset, duration), the product characteristics (phar-
macokinetics, pharmacodynamics), the patient’s pre-
vious response to opioids (efficacy, tolerability), and 
particularly the patient’s preference for an individual 
preparation” [6]. 
The APM guidelines highlighted that “the pharma-
cokinetic/pharmacodynamic profiles of oral opioids 
do not tend to mirror the temporal characteristics of 
most breakthrough pain episodes” [6]. 
A number of “rapid-onset opioids” are now ava-
ilable to treat BTcP (i.e. intranasal formulations, buc-
cal formulations, sublingual formulations). Research 
suggests that they are very effective, and are more 
effective than oral opioids [27, 28]. Moreover, research 
suggests that they are generally very well-tolerated. 
However, the rapid-onset opioids are not a pana-
cea for BTcP. For example, some pains are opioid poorly 
responsive, some pains are ultra-short in duration 
(which limits the efficacy of most pharmacological 
interventions), some patients are intolerant of fenta-
nyl, and some patients have difficulty using specific 
rapid-onset opioids (e.g. patients with xerostomia may 
have difficulty with oral transmucosal formulations).
Recent BTcP guidelines support the preferential 
use of rapid-onset opioids (rather than oral opioids) 
[8, 11, 13, 14], and the recent Delphi processes 
involving Spanish healthcare professionals both repor-
ted high levels of agreement for the use of rapid-onset 
opioids to manage BTcP [15, 16].
It should be noted that some generic cancer pain 
guidelines continue to recommend the use of oral 
opioids to manage BTcP [29, 30]. One of the reasons 
for the continued promotion of oral opioids is the 
need to use as-required medication in patients with 
uncontrolled background pain (i.e. during opioid 
initiation/titration): these flares of pain are often still 
inappropriately referred to as breakthrough pain. 
However, the treatment of choice in this situation is 
invariably an oral opioid (not a rapid-onset opioid). 
Another reason for the continued promotion of the 
use of oral opioids is monetary (i.e. the higher cost of 
rapid-onset opioids vs the cost of oral opioids) [30], 
although the use of ineffective medication will lead 
to increased use of healthcare resources (and thus to 
higher costs) [4].
Titration of rescue medication
The APM recommendations state that the dose of 
rescue medication should be determined by individual 
titration. This advice was based upon data from seve-
ral randomized controlled trials) [31–34], and mirrors 
the advice in the prescribing information (Summary 
of Product Characteristics [SmPC]) for all rapid-onset 
opioids [35]. It should be noted that, although most of 
the data on titration relate to rapid-onset opioids, there 
is analogous data on titration of oral opioids (i.e. oral 
morphine) [32]. This recommendation for titration is 
endorsed by most of the other guidelines [7–9, 11, 14].
Nevertheless, the view has been expressed by 
one key opinion leader that ‘fixed’ doses of rescue 
medication should be used rather than dose titration 
of rescue medication. Thus, it is suggested that the 
dose of rescue medication administered should be 
a proportion of the dose of the background (‘aro-
und the clock’) medication administered [36, 37]. 
Interestingly, however, the Italian BTcP guidelines 
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recommend a hybrid method of rapid titration in 
“highly (opioid) tolerant patients” (i.e. missing out 
some steps/doses) [13]. 
Frequency of rescue medication
The Summary of Product Characteristics (SmPC) 
of most rapid-onset opioids state that they should 
be used to treat no more than four BTcP episodes per 
day, which reflects the maximum usage in the relevant 
pivotal clinical studies [35]. However, there is no phar-
macologic reason to restrict the use of rapid-onset 
opioids to four times daily and, indeed, clinicians do 
so without any problems in selected patients [11].
Abuse/addiction of rescue medication
In many countries, restrictions have been impo-
sed on the prescribing of rapid-onset opioids due to 
concerns about abuse/addiction. However, although 
opioid addiction is a major problem throughout the 
world, it does not appear to be a major problem in 
patients treated for cancer pain [38], or in those tre-
ated for BTcP with rapid-onset opioids [39]. 
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